Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00699166 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
A Phase 2 study of Irritable Bowel Syndrome, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
- 20
- Study locations
NCT00699166: Completed Phase 2 study of Irritable Bowel Syndrome, sponsored by Novartis.
NCT00699166 is a Phase 2 study of Irritable Bowel Syndrome that has completed, run by Novartis. The registered enrollment target is 135 participants, roughly in line with the 141-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00699166, a Phase 2 study of Irritable Bowel Syndrome, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the tolerability, safety and efficacy of DNK333 against diarrhea caused by Irritable Bowel Syndrome in women.
Conditions Studied
Interventions
- DRUG DNK333
Study Locations (20)
California
- - Orange
- - Riverside
- - San Diego
- - Torrance
Alabama
- - Anniston
- - Huntsville
- - Northport
Connecticut
- - Bristol
- - Hartford
Missouri
- - Mexico
- - Washington
Arizona
- - Tucson
Arkansas
- - North Little Rock
Florida
- - Hollywood
Indiana
- - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2004-04 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
What the finished NCT00699166 record still lists
NCT00699166 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 141-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target.
The record links to 1 condition, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which DNK333 is the first listed.
NCT00699166 names 20 study sites across 13 states, led by California, Alabama, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00699166 about?
NCT00699166 is a clinical study titled "Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)". This study will evaluate the tolerability, safety and efficacy of DNK333 against diarrhea caused by Irritable Bowel Syndrome in women.
What is the current status of trial NCT00699166?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2004-04. Estimated completion is 2005-09.
What conditions does trial NCT00699166 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome.
What interventions are being tested in trial NCT00699166?
The interventions under investigation include: DNK333 (DRUG).
Who is sponsoring clinical trial NCT00699166?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00699166 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00699166's enrollment target sits among peer trials
135 16th of 47 higher than 32 of 47 other Irritable Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Irritable Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psyllium in Pediatric IBS
RECRUITING · Phase 2
-
Fecal Microbiota Transplantation for IBS
RECRUITING · Phase 2
-
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
RECRUITING · Phase 2
-
Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)
ACTIVE NOT RECRUITING · Phase 2
-
Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome
COMPLETED · Phase 2
-
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia